5 big analyst AI moves: Apple lifted to Buy, AI chip bets reassessed
South Cone Investments Limited Partnership, a ten percent owner of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI), sold 5,923,000 shares of Class A Common Stock on October 20 and 21, 2025, for a total of $15,711,314. The sales occurred in multiple transactions with prices ranging from $2.4115 to $2.7685 per share. The stock has seen remarkable momentum, surging 234% in the past week, though InvestingPro data indicates it may be overbought. Analysts maintain optimistic price targets between $8-10, suggesting significant upside potential.
On October 20, 1,923,000 shares were sold. Following this transaction, South Cone Investments held 6,379,194 shares. The following day, October 21, the entity sold an additional 4,000,000 shares, reducing their holdings to 2,379,194 shares.
The shares are indirectly held through South Lake One LLC, which is wholly owned by South Cone Investments Limited Partnership.
In other recent news, Rani Therapeutics Holdings Inc. has announced several significant developments. The company entered into a collaboration and license agreement with Chugai Pharmaceutical Co., Ltd. for the development of an oral delivery system for Chugai’s rare disease antibody. This deal includes a $10 million upfront payment to Rani and eligibility for up to $75 million in technology transfer and development milestones, along with potential sales milestones of up to $100 million and single-digit royalties on product sales. Additionally, Rani Therapeutics secured approximately $60.3 million in gross proceeds through a private placement financing. This financing was led by Samsara BioCapital, with participation from RA Capital Management, Anomaly, Special Situations Funds, Invus, and the company’s Executive Chairman Mir Imran. These recent developments mark a significant step forward for Rani Therapeutics in its business endeavors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.